Inovio Pharmaceuticals, Inc. (INO) vs LENSAR Inc (LNSR)
A side-by-side comparison of Inovio Pharmaceuticals, Inc. and LENSAR Inc across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
INO
Inovio Pharmaceuticals, Inc.
$1.14HealthcareDelayed quote: Oct 6, 2026, 10:45 AM EDT
LNSR
LENSAR Inc
$6.64HealthcareDelayed quote: Oct 6, 2026, 10:44 AM EDT
Total return — INO vs LNSR
growth of $100 · dividends reinvested · last 6yINO -99.2% (-55.0%/yr)LNSR -25.9% (-4.9%/yr)LNSR compounded faster over this window
Log scale — wide-divergence pair
INO LNSR
INO vs LNSR: by the numbers
- •LNSR is the larger company ($82M vs $78M market cap).
- •LNSR is profitable (57.57% net margin) while INO runs a net loss (-130000.00%).
Metrics side by side
Valuation
| Metric | INO | LNSR |
|---|---|---|
| P/S ratio | N/A | 1.35 |
| P/B ratio | 17.94 | 5.47 |
Profitability
| Metric | INO | LNSR |
|---|---|---|
| Gross margin | 100.00% | 47.96% |
| Operating margin | -132871.32% | -42.06% |
| Net margin | -130000.00% | 57.57% |
| ROE | -1542.57% | 232.78% |
| ROIC | -836.58% | -16.28% |
Growth (annualized)
| Metric | INO | LNSR |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 14.67% |
| Total return CAGR (5Y) | -57.05% | -3.18% |
Frequently asked
- Is INO or LNSR more profitable?
- LNSR runs the higher net margin — INO at -130000.00% versus LNSR at 57.57%.
- How have INO and LNSR total returns compared?
- Over the past 5 years, INO delivered -57.05% and LNSR delivered -3.18% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Inovio Pharmaceuticals ROELENSAR ROEInovio Pharmaceuticals operating marginLENSAR operating marginInovio Pharmaceuticals revenue growthLENSAR revenue growthInovio Pharmaceuticals free cash flowLENSAR free cash flow
Inovio Pharmaceuticals & LENSAR appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.